Role of endothelial dysfunction and metabolic syndrome in interventional treatment complications development in patients with coronary heart disease

Abstract

Aim. To assess the influence of endothelial dysfunction and metabolic syndrome on interventional treatment coronary complications development in patients with coronary heart disease. Methods. 57 patients with coronary heart disease and concomitant metabolic syndrome (the main group) and 64 patients with coronary heart disease alone (the comparison group) were included in the study. Control group for endothelial function parameters included 33 healthy blood donors. Endothelial function was assessed by plasma and erythrocyte nitrate level, plasma L-arginine level and desquamated endothelial cell blood count before the interventional treatment and after its completion. Results. Initial signs of endothelial dysfunction were observed in both groups of patients compared to the controls. Desquamated endothelial cell blood count was significantly higher in patients with metabolic syndrome than in the comparison group. Only the desquamated endothelial cell blood count increased significantly after the interventional treatment, the difference was more pronounced (р <0.05) in patients with metabolic syndrome. Complications of interventional treatment in patients with and without symptoms of metabolic syndrome were observed in 29.8 and 14.1% respectively (р <0.05). The number of coronary artery restenoses was significantly higher in the main group than in the comparison group (12.2 and 3.1% respectively). Conclusion. Initially endothelial dysfunction was more pronounced in patients with metabolic syndrome. A significant increase of endothelial dysfunction was observed in patients of the main group after the interventional treatment. The number of interventional treatment complications and coronary arteries restenoses was significantly higher in patients with coronary heart disease and concomitant metabolic syndrome.

Keywords

endothelial dysfunction / metabolic syndrome / ischemic heart disease / coronary heart disease / interventional treatment / coronary artery restenosis

References

[1] Арсеничева О.В., Омельяненко М.Г. Снижение риска осложнений интракоронарных вмешательств с помощью ингибиторов АПФ // Паллиатив. мед. и профил. - 2005. - №2. - С. 38.

[2] Данилов Н.М., Горгадзе Т.Т., Савченко А.П. и др. Рестеноз после коронарного стентирования у больных с метаболическим синдромом // Consil. med. - 2006. - Т. 7, №1. - С. 47.

[3] Кириченко Л.Л., Овсянников К.В., Федосеев А.Н. и др. Метаболический синдром как клиническое проявление эндотелиальной дисфункции // Кардиоваск. терап. и профил. - 2012. - №11. - С. 87.

[4] Чазова И.Е., Мычка В.Б. Гиполипидемическая терапия метаболического синдрома // Consil. Med. - 2004. - Т. 6, №5. - С. 296-299.

[5] Шостак М.С., Мазуров В.И. Нарушение гормональной регуляции у больных ишемической болезнью сердца в сочетании с метаболическим синдромом // Эфферент. терап. - 2007. - Т. 13, №1. - С. 82-86.

[6] Mack M. Current status and outcomes of coronary revascularization 1999 to 2002: 148,396 surgical and percutaneous procedures // Ann. Thorac. Surg. - 2004. - Vol. 77, N 3. - P. 761-766.

[7] Mancia J., Bombelli M., Corrao G. et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study daily life bloodpressure, cardiac damage and prognosis // Hypertension. - 2007. - Vol. 49. - P. 40-47.

[8] Myers P.R., Webel R., Thondapu V. et al. Restenosis is associated with decreased coronary artery nitric oxide synthase // Int. J. Cardiol. - 1996. - Vol. 55. - P. 183-191.

[9] Piatti P.M., Colombo A. Association of insulin resistance, hyperleptinemia and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stentin // Circulation. - 2003. - Vol. 108. - Р. 2074-2081.

[10] Reaven G.M. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease // Circulation. - 2002. - Vol. 106. - P. 286-288.

[11] Schwartz R.S. Restenosis and proportional neointimal response to coronary artery injury: results in a porcine model // J. Am. Coll. Cardiol. - 1992. - Vol. 19. - P. 267-274.

[12] Takeki S., Kumiko H., Mitchell S.V. et al. Metabolic syndrome, endothelial dysfunction and risk of cardiovascular events: the Northern Manhattan Study (NOMAS) // Am. Heart J. - 2008. - Vol. 156 - P. 405-410.

[13] Wu T.C., Chen Y.H., Chen J.W. et al. Impaired forearm reactive hyperemia is related to late restenosis after coronary stenting // Am. J. Cardiol. - 2000. - Vol. 85. - P. 1071-1076.

RIGHTS & PERMISSIONS

Arsenitcheva O.V., Omeljanenko M.G.